The pharmaceutical world is ablaze with talk surrounding retatrutide, a potential peptide currently being investigation for obesity conditions. Formulated by Zealand Pharma, retatrutide works as a dual stimulator for both GLP-1 and GIP receptors, modulating appetite and blood sugar metabolism in